Core Insights - CorMedix Inc. reported preliminary unaudited net revenue for Q3 2025 exceeding $125 million, with DefenCath contributing more than $85 million to this total [1][4] - The company has raised its full-year 2025 pro forma net revenue guidance to at least $375 million, up from the previous range of $325-$350 million [1][4] - CorMedix anticipates achieving approximately $30 million in operating synergies on a go-forward run-rate basis before the end of 2025 [1][4] Financial Performance - Preliminary Q3 2025 unaudited net revenue is reported to be over $100 million, with DefenCath revenue growth driven by higher utilization from LDO customers and other clients [4] - The company expects adjusted EBITDA for Q3 2025 to be at least $70 million [4] - As of September 30, 2025, cash, cash equivalents, and short-term investments totaled approximately $56 million, with a projected year-end balance of around $100 million [4] Business Developments - CorMedix has made significant progress in integrating the recently acquired Melinta portfolio, with expected cost synergies of $30 million before Q4 2025 and an additional $5-$15 million targeted for 2026 [4] - The company has completed enrollment in the Phase III ReSPECT study for Rezzayo, aimed at preventing fungal infections in patients undergoing allogeneic blood and marrow transplants, with clinical data expected in Q2 2026 [4][6] - The total addressable market for prophylaxis is estimated to exceed $2 billion [4] Product Portfolio - CorMedix is focused on developing and commercializing therapeutic products for life-threatening conditions, including DefenCath for preventing catheter-related bloodstream infections [5] - Following the acquisition of Melinta Therapeutics, the company is also commercializing a range of anti-infective products, including MINOCIN, REZZAYO, VABOMERE, ORBACTIV™, BAXDELA, and KIMYRSA [5]